血液科

订阅

MedSci主页 / 所有栏目 / 血液科

欧盟批准血小板减少症药物Doptelet

2020-11-06 MedSci原创 MedSci原创

血小板减少症血小板生成素受体激动剂Doptelet（avatrombopag）
关注

Doptelet通过模拟血小板生成素刺激巨核细胞发育和成熟，增加血小板数量。

Sobi公司的血小板生成素受体(TPO-R)激动剂Doptelet（avatrombopag），在欧盟获批用于治疗成人慢性肝病（CLD）患者的严重血小板减少症。

血小板减少症的特征是血液中血小板数量减少，这是CLD患者常见的并发症。随着肝脏疾病病变更加严重，血小板减少症的程度通常也会恶化。Doptelet是通过模拟血小板生成素刺激巨核细胞发育和成熟的生物学作用，增加血小板数量。

Avotrombopag Illustration by Jackie Heda | Medical Illustration & Animation

在两项ADAPT-1和ADAPT-2 III期临床试验中，Doptelet在患有严重血小板减少症的CLD患者中进行治疗时，可有效增加血小板数量和减少血小板输注治疗。

Doptelet先前也获得了美国食品和药物管理局（FDA）的批准，用于治疗CLD成年患者的血小板减少症。

原始出处：

http://www.pharmatimes.com/news/sobi_launches_thrombocytopenia_med_doptelet_in_eu_1355930

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=897663, encodeId=288189e66387, content=重肝患者的福利, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a22279351, createdName=noboaty, createdTime=Sun Nov 08 07:53:22 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302856, encodeId=2e1213028567b, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562089, encodeId=a5611562089d9, content=<a href='/topic/show?id=45f2618819' target=_blank style='color:#2F92EE;'>#Doptelet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6188, encryptionId=45f2618819, topicName=Doptelet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c9b15261314, createdName=cy0329, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590035, encodeId=17d6159003524, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
    2020-11-08 noboaty

    重肝患者的福利

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=897663, encodeId=288189e66387, content=重肝患者的福利, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a22279351, createdName=noboaty, createdTime=Sun Nov 08 07:53:22 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302856, encodeId=2e1213028567b, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562089, encodeId=a5611562089d9, content=<a href='/topic/show?id=45f2618819' target=_blank style='color:#2F92EE;'>#Doptelet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6188, encryptionId=45f2618819, topicName=Doptelet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c9b15261314, createdName=cy0329, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590035, encodeId=17d6159003524, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
    2020-11-08 lingaifan

    #血小板减少#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=897663, encodeId=288189e66387, content=重肝患者的福利, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a22279351, createdName=noboaty, createdTime=Sun Nov 08 07:53:22 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302856, encodeId=2e1213028567b, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562089, encodeId=a5611562089d9, content=<a href='/topic/show?id=45f2618819' target=_blank style='color:#2F92EE;'>#Doptelet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6188, encryptionId=45f2618819, topicName=Doptelet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c9b15261314, createdName=cy0329, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590035, encodeId=17d6159003524, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
    2020-11-08 cy0329

    #Doptelet#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=897663, encodeId=288189e66387, content=重肝患者的福利, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a22279351, createdName=noboaty, createdTime=Sun Nov 08 07:53:22 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302856, encodeId=2e1213028567b, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562089, encodeId=a5611562089d9, content=<a href='/topic/show?id=45f2618819' target=_blank style='color:#2F92EE;'>#Doptelet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6188, encryptionId=45f2618819, topicName=Doptelet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c9b15261314, createdName=cy0329, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590035, encodeId=17d6159003524, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 08 06:53:34 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
    2020-11-08 chenwq14

    #欧盟批准#

    0

相关资讯

如何识别肝素诱导的血小板减少症

肝素和低分子肝素作为抗凝剂在临床上应用广泛，例如经皮冠状动脉介入治疗（PCI）、心脑血管外科手术、体外循环、血液透析、动静脉导管留置等治疗和操作。

孤儿药avatrombopag用于化疗诱导的血小板减少症三期临床失败

近日，瑞士孤儿药制药商Swedish Orphan Biovitrum（Sobi）公布了一种口服血小板生成素（TPO）受体激动剂Doptelet®（avatrombopag）用于实体瘤患者化疗

Blood：芳香化酶是cereblon的新底物，参与IMiDs诱导性血小板减少症的发生

IMiDs诱导芳香化酶降解，影响人巨噬细胞的雌二醇自分泌信号。 IMiDs介导的芳香化酶降解通过抑制血小板前体的形成诱发血小板减少症。

J Thromb Haemost：COVID-19患者血小板减少症与死亡率的关系

血小板减少症在COVID-19患者中很常见，并且与院内死亡风险增加相关。COVID-19患者血小板数越少，死亡率越高。

Brit J Heamatol：巨细胞病毒相关血小板减少症患者的特征和预后

血小板减少症患者的这些独特特征提醒医务人员CMV感染可能是原因。虽然不到三分之一的病例对类固醇治疗有效，但抗CMV治疗和TPO-RA均具有较好的疗效，这表明应该更早地采用这些药物治疗。

中国NMPA批准针对成年慢性肝病患者的血小板减少症药物——血小板生成素激动剂DOPTELET

AkaRx公司宣布其DOPTELET（avatrombopag）已获得中国国家药品监督管理局（NMPA）的批准，用于治疗计划接受手术的成年慢性肝病（CLD）患者的血小板减少症。